A prespecified interim analysis of a phase 3 trial shows atacicept produced a 45.7% proteinuria reduction versus 6.8% with placebo at 36 weeks. Phase 2 data for sibeprenlimab, cemdisiran, and felzartamab also show promising antiproteinuric effects but need confirmatory outcomes.